Conditional survival disparities and determinants in Urban-Rural patients with papillary thyroid carcinoma [0.03%]
城乡分化与乳头状甲状腺癌患者生存率的影响因素分析
Xiaoyu Ji,Ruonan Yu,Yue Yu et al.
Xiaoyu Ji et al.
Clinical and Genetic Profile of Chinese Familial Hypocalciuric Hypercalcemia Type 1 (FHH1): A Retrospective Study [0.03%]
中国 Famhh1 患者的临床及基因型特征:一项回顾性研究
Liyuan Kou,An Song,Min Nie et al.
Liyuan Kou et al.
BRAF/MEK inhibitors for redifferentiation in patients with radioiodine refractory thyroid cancer: A systematic review and Meta-Analysis [0.03%]
用于放射性碘难治性分化型甲状腺癌患者红分化治疗的BRAF/MEK抑制剂：系统评价和Meta分析
Kexin Shi,Xinyue Zhang,Chenyu Sun et al.
Kexin Shi et al.
Reply to" comment on "Adrenal lesions in patients with abdominal multitrauma" by Parasa et al [0.03%]
对Parasa等“腹部多发伤患者肾上腺病变”的评论的答复
Anna Kistner,Henrik Falhammar
Anna Kistner
3β-Hydroxysteroid dehydrogenase type-2 deficiency: Our experience and gonadal function-focused systematic review [0.03%]
3β-羟基类固醇脱氢酶2型缺乏症：我们的诊疗经验及以性腺功能为重点的系统评价
Aaditya Daga,Aditya Phadte,Manjiri Karlekar et al.
Aaditya Daga et al.
Phenotypic variability in Klinefelter syndrome: clinical findings including reported fatherhood [0.03%]
克兰费尔特综合征的表型变异：临床发现包括报道的父性生育能力
İlyas Yücel,Gülbahar Güzel Erdal,Ğarip Demir et al.
İlyas Yücel et al.
MiR-342-3p is a novel biomarker for the diagnosis and regulates tumorigenesis in thyroid papillary cancer through FOXQ1 [0.03%]
新型miRNA生物标志物MiR-342-3p通过FOXQ1调控甲状腺乳头癌的发生发展机制研究
Ying Li,Wei Chen,Ling Zhang et al.
Ying Li et al.
A Hospital-Wide informatized glycemic management Team(WH-GMT) improves perioperative outcomes in type 2 diabetes: A prospective cohort study [0.03%]
医院全面信息化血糖管理团队（WH-GMT）改善2型糖尿病患者的围手术期结局：前瞻性队列研究
Qianlin Zhou,Xiaojie Pan,Xiaofang Zhang et al.
Qianlin Zhou et al.
Purpose: To evaluate the effectiveness of the Hospital-Wide Informatized Glycemic Management Team (WH-GMT) model on perioperative outcomes in patients with type 2 diabetes mellitus (T2DM). ...
Differential diagnosis of familial dysalbuminemic hyperthyroxinemia , RTH, and TSHomas: A single-center retrospective analysis [0.03%]
家族性异型血清白蛋白症、抵抗素综合征和TSH瘤的鉴别诊断：一项单中心回顾性分析
Yuanmeng Li,Ke Zhang,Xiaofeng Chai et al.
Yuanmeng Li et al.
Baxdrostat for the treatment of primary aldosteronism: current evidence [0.03%]
巴索 drostat 治疗原发性醛固酮增多症的现有证据
João Menino,Arturo Vega,Jessica Goi et al.
João Menino et al.